Tremfya is used to treat certain types of plaque psoriasis and psoriatic arthritis [1][2]. Specifically, it is indicated for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [1]. It is also used for active psoriatic arthritis in adults [2].
How does Tremfya work?
Tremfya, also known by its generic name guselkumab, is a medication that works by inhibiting a protein called interleukin-23 (IL-23) [1][3]. IL-23 is a naturally occurring protein in the body that plays a role in inflammation [3]. By blocking IL-23, Tremfya helps to reduce the inflammation associated with plaque psoriasis and psoriatic arthritis [1][2].
How long does Tremfya take to start working?
Many patients using Tremfya experience significant skin improvement within weeks of starting treatment [1]. Clinical studies have shown that a substantial percentage of patients achieve clear or almost clear skin by week 16 [1].
What is the difference between Tremfya and other psoriasis treatments?
Tremfya is a biologic medication that targets IL-23, a specific pathway involved in inflammatory skin diseases [1][3]. Other psoriasis treatments may include topical creams, oral medications, or other types of biologics that target different inflammatory pathways, such as TNF-alpha inhibitors or IL-17 inhibitors [4]. The choice of treatment often depends on the severity of the condition, individual patient factors, and response to previous therapies [4].
When does Tremfya's patent expire?
Information on specific patent expiry dates for Tremfya is available through resources that track pharmaceutical patents [5]. DrugPatentWatch.com provides detailed patent information, including expiration timelines for many medications [5].
Are there any risks or side effects associated with Tremfya?
Like all medications, Tremfya can cause side effects. Common side effects include upper respiratory infections, headache, fatigue, and injection site reactions [1]. More serious, though less common, side effects can include increased risk of infections [1]. Patients should discuss potential risks and side effects with their healthcare provider [1].
Can Tremfya be used for other conditions?
Currently, Tremfya is approved for moderate to severe plaque psoriasis and active psoriatic arthritis in adults [1][2]. Research into its potential use for other inflammatory conditions may be ongoing.
Who makes Tremfya?
Tremfya is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [1].
Where can I find more information about Tremfya patents and exclusivity?
Detailed information regarding the patent status and market exclusivity of Tremfya can be found through specialized pharmaceutical patent tracking services. DrugPatentWatch.com offers comprehensive data on drug patents and their expiration dates [5].
Sources:
[1] https://www.tremfya.com/
[2] https://www.janssen.com/our-products
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507859/
[4] https://www.psoriasis.org/about-psoriasis/treatments/biologics/
[5] https://drugpatentwatch.com/